Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,602

Document Document Title
WO/2020/188183A1
The invention relates to a process for producing a polybenzoxazine monomer, the crosslinking thereof, and the use of the crosslinked product to form ablative thermal protection for a propelling nozzle or a body for atmospheric re-entry.  
WO/2020/188182A1
The invention relates to a process for producing a polybenzoxazine monomer, the crosslinking thereof and the use of the crosslinked product to form an ablative thermal protection for a thruster nozzle or an atmospheric re-entry body.  
WO/2020/176501A1
The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, RA, RB, RC, RD, L0, L1, L2, and L2, are defined herein. Compounds and salts of ...  
WO/2020/170080A1
A hydrofluoroolefin compound is represented by the following general formula (I): where RF1 is a hydrogen atom or CH3, and (iii) RF1 is a linear or branched perfluorinated alkyl group having 1 to 10 carbon atoms and optionally including ...  
WO/2020/163464A1
A curable composition, a method of making the curable composition, and an article and product produced therefrom are provided. A morpholinedione is contacted with an isocyanate to form a resin composition. The resin composition is reacte...  
WO/2020/152037A1
A radiation curable inkjet ink containing at least one or two compounds selected from the group consisting of a polymerizable compound including a vinylether group or a vinylamide group, an amine synergist including an alkanolamine group...  
WO/2020/145250A1
[Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.  
WO/2020/076274A3
The present invention is related to unique caffeic acid phenethyl ester (CAPE) analogues, methods for preparation of said molecules, and the usage of said unique molecules in the preparation of a pharmaceutical composition that is to be ...  
WO/2019/090085A8
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).  
WO/2020/127319A1
The present invention relates to the combination of sulfonamide derivatives which are ABA agonists and at least one additional active ingredient selected from the group consisting of fungicides/bactericides, insecticides/acaricides and a...  
WO/2020/127386A1
A method is provided for preparing an intermediate d having the formula: (I). The method comprising carrying out the following one-pot reaction: (II) wherein step (i) is carried out in the presence of a solvent and step (ii) is carried o...  
WO/2020/127390A1
A method is provided for preparing a compound d having the formula (D) The method comprises carrying out the following reaction (c) → (d), where the reaction is carried out at a temperature of at least 100 °C and in the presence of a ...  
WO/2020/124771A1
The present invention relates to a thermally activated delayed fluorescent compound, a preparation method therefor and an organic electroluminescent diode device thereof. The thermally activated delayed fluorescent compound has a structu...  
WO/2020/127385A1
A method is provided for preparing a compound d having the formula: Formula (I). The method comprises carrying out the following reaction: Formula (i), (ii), (d) where: step (i) is carried out in the presence of a metal catalyst and a hy...  
WO/2020/106642A1
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.  
WO/2020/098114A1
Disclosed are a thermally activated delayed green light fluorescent material, a synthesis method thereof, and an electroluminescent device comprising same. The thermally activated delayed green light fluorescent material is a target comp...  
WO/2020/094528A1
The present invention relates to novel processes for the enantioselective iridium-catalysed hydrogenation of oximes and oxime ethers to provide compounds of formula (II) and salts thereof formula (I) and (II).  
WO/2020/092383A1
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processe...  
WO/2020/082601A1
Disclosed are a dark red photothermally activated delayed fluorescence material, a synthesis method therefor and an electroluminescent device. The dark red photothermally activated delayed fluorescence material is a target compound, whic...  
WO/2020/081836A1
The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.  
WO/2020/077884A1
Provided are an electroluminescent material, a method for preparing an electroluminescent material, and a light emitting device. The preparation method comprises: using a reaction between 2,7-dibromofluorene and bromohexyl to generate a ...  
WO/2020/072377A1
The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin s...  
WO/2020/054218A1
A purpose of the present invention is to provide a benzoxazine compound usable in a curable resin composition which has excellent pliability before curing and has excellent dielectric properties after curing. Another purpose of the prese...  
WO/2020/046335A1
Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as CMA modulators. The disclosure provides pharmaceutical compositions containing a compound of Formu...  
WO/2020/045856A1
The present invention relates to a novel hypoxia-inducible factor 1α (HIF-1α) inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating angiogenesis-associated eye disease, containing same as...  
WO/2020/039094A1
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/020178A1
An organic compound as shown in formula (1). Ar 2 has a structural formula as shown in formula (2), and a plurality of Ar 2 may be the same or different. The compound as shown in formula (1) can be used as a luminescent layer material of...  
WO/2020/019529A1
The present invention relates to a preparation method for 4-(4-aminophenyl) morpholin-3-one. Said method comprises: using p-nitroaniline as a raw material, successively performing an amidation reaction and a catalytic hydrogenation react...  
WO/2019/240099A1
Provided is a novel benzoxazine compound which has a low melting point and a low curing reaction temperature and rarely undergo thermal decomposition and therefore has a high weight retention ratio during a curing reaction, and which is ...  
WO/2019/234405A1
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of For...  
WO/2019/223732A1
The present invention relates to a p-phenylenediamine derivative as a potassium channel regulator and a preparation method and medical application thereof. In particular, disclosed is a compound represented by general formula A or a phar...  
WO/2019/220293A1
Described herein is a perfluorinated aminoolefin compound of general formula (I): CFY=CXN(Rf)CF2Rf' where: (a) Rf and Rf' are (i) independently selected from a linear or branched perfluoroalkyl group having 1-8 carbon atoms, optionally c...  
WO/2019/219016A1
Provided by the present invention are an acrylic compound and a preparation method therefor and a pharmaceutical composition and application thereof. In particular, the present invention provides a compound of formula I, wherein each gro...  
WO/2019/199621A4
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...  
WO/2019/217307A1
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and me...  
WO/2019/216810A1
Compounds of the formulae wherein the bond α is a single bond, a trans double bond (E), or a triple bond; X and Y are -CH2- or on of X and Y is O and the other is CH2; R1 is phenyl unsubstituted or substituted with one, two, or three su...  
WO/2019/199621A1
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...  
WO/2019/199864A1
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...  
WO/2019/193544A1
The present disclosure is related to the synthesis and applications of a benzo[a]phenoxazine. It displays good photophysical properties, such as high molar extinction coefficient, good fluorescence quantum yield and solubility in water. ...  
WO/2019/193159A1
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporter...  
WO/2019/190177A1
The present application relates to a novel pentadieonyl compound and a pharmaceutical composition comprising same. Functioning to restrain intracellular adipogenesis and fat accumulation within cells and to activate fat metabolism, the p...  
WO/2019/175897A1
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...  
WO/2019/167080A1
The present invention disclosed herein is a bile acid sequestering composition comprising the resin chelate with improved affinity/binding activity towards bile acid(s) and to the process for preparation thereof.  
WO/2019/161224A1
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.  
WO/2019/129593A3
A method for preparing a substituted fuel additive d is provided. The method comprises carrying out the following reaction: ( a, b, d ) A is selected from halides and -SO3R13, where R13 is selected from hydrogen, alkyl groups and alkali ...  
WO/2019/118785A3
The present disclosure relates generally to therapeutic agents that may be useful inhibitors of Integrated Stress Response (ISR) pathway.  
WO/2019/138362A1
The field of this invention relates to a novel process, suitable for industrial scale manufacture, for the preparation of 4-(4-aminophenyl)morpholin-3-one of Formula (I), the key intermediate of rivaroxaban according to the scheme. In th...  
WO/2019/129592A1
A method for preparing a fuel additive d is provided. The method comprises carrying out the following reaction: (l) The fuel additive d may be used as an octane-boosting additive in a fuel for a spark, ignition internal combustion engine.  
WO/2019/129589A1
An optimised method for preparing a fuel additive f is provided. The method comprises carrying out the following reaction: (c, d, e) Starting material c may be prepared using an optimised method which comprises carrying out the following...  
WO/2019/129594A1
A method for preparing a substituted fuel additive d is provided. The method comprises carrying out the following reaction: Each Y is independently selected from halides, and X is selected from -O- or -NR10-.  

Matches 1 - 50 out of 6,602